EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy

Huixian Li, Li Jin, Xinfang Xie, Jiping Sun, Dan Niu, Jie Feng, Guiqing Xu, Xiaotian Zhang, Abdulrahman Majeed S Khalaf, Wanhong Lu

American Journal of Nephrology · 19.05.2025 · 57 (1) · 21-29

DOI: 10.1159/000545995 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Nephrology, online erschienen am 19.05.2025. Verfasst von Huixian Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Rituximab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Rituximab has become the first-line therapy for patients with membranous nephropathy (MN). However, approximately 30–40% of patients with MN do not respond to rituximab. We presented our single-center experience of treating rituximab-refractory MN with obinutuzumab which is a humanized and glycoengineered type II anti-CD20 monoclonal antibody.

Methods

Seventeen patients with rituximab-refractory phospholipase A2 receptor (PLA2R)-associated MN who received obinutuzumab at the First Affiliated Hospital of Xi’an Jiaotong University were included in this case series study. Clinical and laboratory parameters were evaluated at presentation, before and after obinutuzumab administration.

Results

Of all patients with an average age of 49.7 ± 13.7 years, 11 (64.7%) patients were men. The median disease duration was 12 (12, 42) months. At presentation, the proteinuria and serum albumin levels were 7.51 ± 3.55 g/day and 22.1 ± 3.6 g/L, respectively. The mean estimated glomerular filtration rate level was 103.5 ± 12.9 mL/min/1.73 m2, and the patients had a baseline anti-PLA2R level of 183.2 ± 92.9 RU/mL. At obinutuzumab administration, proteinuria and albumin levels were still consistent with nephrotic syndrome. After a median follow-up of 12.6 ± 5.0 months, complete remission was achieved in 9 (52.9%) and partial remission was achieved in 6 (41.2%) cases. Of the patients who achieved remission, the median remission time was 4.4 (4.0, 6.0) months. At 6 months, 12 (70.6%) patients achieved remission and 11 of 12 patients with available PLA2R measurements reached immunological remission.

Conclusion

Obinutuzumab may represent an attractive alternative therapy in rituximab-refractory patients. Larger prospective studies are needed to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, MembranousRituximabAntibodies, Monoclonal, HumanizedHumansMaleMiddle AgedFemaleRemission InductionAdultReceptors, Phospholipase A2Retrospective StudiesTreatment OutcomeAgedProteinuriaGlomerular Filtration RateDrug ResistanceDrug Therapy, Combination

Stichwörter der Autor:innen

Anti-phospholipase A2 receptor antibodyMembranous nephropathyObinutuzumabRituximab-refractory

Substanzen

RituximabAntibodies, Monoclonal, HumanizedobinutuzumabReceptors, Phospholipase A2

Autor:innen und Institutionen

  • Department of Nephrology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Department of Human Anatomy, Histology and Embryology, Xi'an Jiaotong University Health Science Center, Xi'an, China.
  • Department of Nephrology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, luwanhong@xjtu.edu.cn.

Zitieren

APA

Li, H., Jin, L., Xie, X., Sun, J., Niu, D., Feng, J., Xu, G., Zhang, X., Khalaf, A. M. S., & Lu, W. (2025). Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy. American Journal of Nephrology, 57(1), 21-29. https://doi.org/10.1159/000545995

Vancouver

Li H, Jin L, Xie X, Sun J, Niu D, Feng J, et al. Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy. American Journal of Nephrology. 2025;57(1):21-29. doi:10.1159/000545995

BibTeX
@article{Li2025,
  author = {Li, Huixian and Jin, Li and Xie, Xinfang and Sun, Jiping and Niu, Dan and Feng, Jie and Xu, Guiqing and Zhang, Xiaotian and Khalaf, Abdulrahman Majeed S and Lu, Wanhong},
  title = {Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy},
  journal = {American Journal of Nephrology},
  year = {2025},
  volume = {57},
  number = {1},
  pages = {21--29},
  doi = {10.1159/000545995}
}
Kostenlos starten →